Takeda
Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease
July 23, 2019Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …
Top Ten most popular articles on Pharmafile.com this week
June 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit
This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …
Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
June 26, 2019Manufacturing and Production, Medical Communications, Sales and Marketing Shire, Takeda, US, pharma
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, Illinois, by the end of …
Takeda’s Ninlaro fails to meet one of two primary endpoints in Phase 3 trial
June 6, 2019Research and Development TOURMALINE-AL1, Takeda, pharma, phase 3, trial Ninlaro
Takeda has decided to discontinue its Phase 3 study of Ninlaro (ixazomib) after the drug in combination with dexamethasone, failed …
Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show
May 20, 2019Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis
Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
May 9, 2019Business Services, Medical Communications, Sales and Marketing Novartis, Shire, Takeda, debt, pharma, xiidra
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal …
Takeda opens R&D facility in San Diego, California
May 2, 2019Manufacturing and Production, Research and Development CNS, GI, Japan, Takeda, california, neuroscience, san diego
Japanese-firm Takeda pharmaceuticals has opened a new research facility in San Diego, California. The 165,000ft2 research centre will employ 250 …
NICE recommend Takeda’s lymphoma treatment Adcetris
March 25, 2019Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …
Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma
February 14, 2019Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma
Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …
Takeda ordered to pay Bayer $155.19 million over patent infringement
February 6, 2019Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate
A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …
Takeda’s dengue vaccine proves efficacious in massive Phase 3 trial
January 30, 2019Research and Development Dengue fever, TAK-003, Takeda, Vaccine, dengue, health, infectious diseases
Takeda’s dengue vaccine candidate TAK-003, has proved efficacious in preventing dengue fever in healthy children and adolescents in an ongoing …
Top Ten most popular articles on Pharmafile.com this week!
January 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, Shire, Takeda, bristol myers squibb, death row, pharma, top 10
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger merger was announced as US …
Takeda completes Shire acquisition
January 8, 2019Manufacturing and Production M&A, MA, Shire, Takeda, acquisition, deal, pharma
Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm …
Takeda unveils three new discovery and development collaborations in immuno-oncology
January 4, 2019Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma
Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …
Top Ten most popular articles on Pharmafile.com this week!
December 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit
Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
